Trials / Conditions / Tenosynovial Giant Cell Tumor

Tenosynovial Giant Cell Tumor

19 registered clinical trials studyying Tenosynovial Giant Cell Tumor — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) NCT07499362	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	Phase 2
Recruiting	Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery NCT07315841	Shanghai Jiao Tong University Affiliated Sixth People's Hospital	Phase 4
Recruiting	Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib NCT07075471	Deciphera Pharmaceuticals, LLC	—
Active Not Recruiting	Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER) NCT05804045	Abbisko Therapeutics Co, Ltd	Phase 3
Completed	A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT NCT05349643	AmMax Bio, Inc.	Phase 2
Active Not Recruiting	Study of Vimseltinib for Tenosynovial Giant Cell Tumor NCT05059262	Deciphera Pharmaceuticals, LLC	Phase 3
Terminated	A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients NCT04938180	AmMax Bio, Inc.	Phase 2
Completed	An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of th NCT04731675	AmMax Bio, Inc.	Phase 2
Active Not Recruiting	A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan NCT04703322	Daiichi Sankyo Co., Ltd.	Phase 2
Recruiting	A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment NCT04635111	Daiichi Sankyo	—
Completed	Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) P NCT04526704	Daiichi Sankyo	Phase 4
Active Not Recruiting	A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT NCT04488822	Daiichi Sankyo Co., Ltd.	Phase 3
Recruiting	A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid T NCT04192344	Abbisko Therapeutics Co, Ltd	Phase 1
Active Not Recruiting	Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor NCT03069469	Deciphera Pharmaceuticals, LLC	Phase 1 / Phase 2
Terminated	A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor NCT02673736	Plexxikon	Phase 1
Completed	Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cel NCT02471716	Five Prime Therapeutics, Inc.	Phase 1 / Phase 2
Completed	Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sh NCT02371369	Daiichi Sankyo	Phase 3
Terminated	Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors NCT01804530	Plexxikon	Phase 1
Completed	Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tum NCT01207492	Andrew J. Wagner, MD, PhD	Phase 2